IPUBLIC RECORDSEXCHANGERECEIPTSloadinglive·IMONEY TRAILEXCHANGESOURCESverifyinglive·IDATA SOURCESEXCHANGEFILINGSpublic recordslive·IPUBLIC RECORDSEXCHANGERECEIPTSloadinglive·IMONEY TRAILEXCHANGESOURCESverifyinglive·IDATA SOURCESEXCHANGEFILINGSpublic recordslive·
← Today’s Receipts
Public-record receiptD-OROfficial filing linked

Ron Wyden disclosed SELL $LLY

Here’s the public record: who traded, what they disclosed, when it happened, how late it appeared, and what context is attached.

Trade range
$50K – $100K
Filed
2025-02-21
Trade date
2025-02-10
Disclosure lag
11 days after trade

Why this receipt matters

A quick read before you share it.

These are factual context points from the receipt and linked public-record data. They explain why the disclosure may be worth opening, not whether anyone acted improperly.

Official public filing linked
1The receipt links to an official public filing, so readers can verify the underlying disclosure before sharing.
2The filing appeared 11 days after trade, which helps separate trade timing from filing timing.
3The disclosed range is $50K – $100K, which is the public reporting band rather than an exact profit or loss figure.
411 nearby same-ticker disclosures appeared in the surrounding 30-day window.
5Committee context is available for Ron Wyden, but PoliWealth treats it as context - not proof of intent or wrongdoing.
6Related public-record context includes 17 lobbying filings.

Source

Official filing ↗
Source: official House/Senate financial disclosure record · filing ID f3e6926f-70d4-4265-9b81-68798dfc73bb · filed 2025-02-21 · disclosed 11d after transaction

Market context

Eli Lilly and Company

Sector: Healthcare

Vs SPY: -11.5%

Factual flags

  • 17 lobbying filings linked to this ticker.
  • 11 nearby same-ticker disclosures in the surrounding 30-day window.
  • 4 committee-overlap trades landed within 30 days in the healthcare,pharma,biotech sector; treat this as a public-record clustering signal only.
  • LLY transaction date was 3d after a public lobbying filing by ELI LILLY AND COMPANY ($1,900,000); committee-sector context: Financials; this is timing context, not a finding of intent.
  • Committee coverage overlaps the healthcare/pharma/biotech sector for LLY; this is contextual public-record overlap, not a finding of intent.
  • Disclosed range upper bound: $100,000.

Member trail

Ron Wyden

U.S. Senate · OR

Senate Committee on Energy and Natural ResourcesSenate Committee on FinanceSenate Committee on the BudgetJoint Committee on TaxationSenate Select Committee on Intelligence

Ticker trail

$LLY

Eli Lilly and Company

Follow this ticker

Alert me when this ticker gets a new congressional receipt. This page reports public disclosures and factual context only. It does not determine intent, is not an accusation, and is not investment advice.